Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability
Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability
Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability
Submitted by
admin
on June 5, 2016 - 11:48am
Source:
Yahoo
News Tags:
Juno Therapeutics
CD19
CAR-T
ASCO 2016
B-cell malignancies
Headline:
Juno Therapeutics’ Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability
Do Not Allow Advertisers to Use My Personal information
